Cancers of the brain and CNS comprize a group of rare and heterogeneous tumors with respect to genetics and biology. 1 They constitute approximately 3% of the cancer cases worldwide and are more frequent among men than women. 2 The prognoses of brain and CNS cancers vary by age and histological type; generally 5-year survival is low, with prognosis particularly poor for glioblastomas and at older ages. 3 Observed increases in survival in higherincome countries are largely attributed to improvements in medical care and the availability of new therapies. 4, 5 Studies, particularly in Western countries, have indicated an increasing occurrence of brain and CNS cancers, most notably among elderly populations. [6] [7] [8] The main driver is considered to be general improvements in diagnosis following the introduction of CT and MRI in the 1980s. 6,7 Little is known about the etiological factors of brain cancers. Other than genetic risk factors, ionizing radiation exposure is known to increase the risk, while allergic conditions appear to decrease its risk. 9,10 Exposure to non-ionizing radiation, especially radiofrequency fields from mobile phones but also low frequency fields, infections with some viruses, use of hormonal contraceptives, hormone replacement therapy, statins, vitamin D level, alcohol, height, BMI, and occupational exposures have been investigated, but no firm conclusions can be drawn at present. [11] [12] [13] Given the specific anatomical location of brain and CNS tumors and the high probability of developing a life-threatening condition, many cancer registries record (and include in reporting) nonmalignant tumors of the brain and other and unspecified parts of the CNS. These 
NeuroOncology
nonmalignant tumors are estimated to be around twothirds of all brain and CNS tumors. 14 This fact in combination with the underlying diagnostic difficulties of these tumors, 15 the lack of consistency in definition of specific histological types, and the importance of diagnostic advances with time calls for a careful assessment of international comparisons of secular trends in incidence 16 ; in some instances such comparisons may not be valid 17 Perhaps for the above reasons, systematic descriptions of the patterns and trends of brain and CNS cancers across world regions are rarely undertaken. They can, however, contribute to a better understanding of the specific problems of interpretation and may provide some insight into potential risk factors and consequently the future burden of these tumors. The present study aims to provide such a global status report of the geographic and temporal variations in the incidence of brain and CNS cancers in different countries across continents worldwide.
Methods

Data Sources
Annual incidence data of cancers of the brain and CNS (including malignant meningioma, ICD-10: C70-72) were derived from International Agency for Research on Cancer's serial publication Cancer Incidence in Five Continents (CI5) volumes VIII, IX, and X (1993 to 2007) 18 and additionally extracted from the European Cancer Observatory for Denmark, Norway, and Sweden. 19 Incidence data in the CI5 publications were obtained from high quality populationbased registries covering either the total population (in 17 countries) or region(s) within a given country. We included 96 registries in 39 countries (see Supplementary Table 2 ) across 9 world regions: (1) Africa, (2) Central and South America, (3) Northern America, (4) Asia, (5) central and eastern Europe (6) northern Europe, (7) southern Europe, (8) western Europe, and (9) Oceania.
Statistical Analysis
Data were analyzed in adult populations (≥15 y, due to different patterns of brain and CNS cancer in children) by sex and country except in the US, where separate analysis by race/ethnicity (US whites and US blacks) were undertaken. Truncated age-standardized incidence rates (per 100,000, ages ≥15 y) used the world standard population 20 21 and presented with corresponding 95% CIs for each country, except Uganda, excluded from this analysis due to small numbers. An AAPC with an associated P value <.05 was considered statistically significant. The choice of model was determined using a permutation method. 21 All analyses were performed using the statistical software Stata and Joinpoint (batch mode). 22 Trends in incidence by sex are shown with smoothed lines on fitting locally weighted regression (lowess) curves, in which 30% of the data were used in the smoothing. 23 
Results
Geographic Variations in Incidence 2003-2007
In the countries/registries considered, 78,034 new cases of brain and CNS cancers were diagnosed between 2003 and 2007; 54% in men and 46% in women (Table 1) . Incidence was generally higher in men than in women, with a male to female ratio ranging from 2.7 to 1.0. Age-standardized incidence rates (per 100,000) in men were highest in Brazil (13.3), Croatia (12.0), and Poland (9.8), followed by the northern European countries of Iceland (9.5), Latvia (9.2), Denmark, and Norway (both 9.0). For women, rates in Croatia ranked first (9.4), followed by Poland (9.2), Brazil (7.9), Iceland (7.6), and Latvia (7.6). Rates were lowest among men in Thailand (2.4), Japan (2.6), Uganda (2.6), and Singapore (2.9), and in Uganda (1.0), Japan (1.8), Singapore (2.2), and Thailand (1.0) among women. Large differences were observed between the white and black populations of the US, with an almost 2-fold higher incidence among whites relative to blacks (8.3 vs 4.4 in white and black men and 6.0 vs 3.6 in women, respectively) ( Fig. 1 
Temporal Variations 1993-2007
Figures 2, 3, and 4 show the annual incidence rate for each country included in this study by sex, between 1993 and 2007. Rising trends were observed in both sexes in Latvia, Lithuania, Norway, Slovenia, the Russian Federation, Ecuador, Colombia, Brazil, Singapore, and Thailand; in the remaining countries, rates tended to be relatively stable over the last decade.
The AAPC for the last 10 years (commonly 1998-2007) is shown in Fig. 5 . Generally about half of the countries exhibited an increasing incidence of brain and CNS cancer. Elsewhere, brain and CNS cancer rates have been quite stable or showing minor declines; only among Japanese men was there a significant decrease in rates over time (AAPC: -1.2%). In contrast, a marked annual increase was found in many South American countries: in Brazil, Colombia, and Ecuador with mean increases of 3.3%, 1.3%, and 1.1% per annum, respectively. Two countries in eastern Europe (Poland and the Russian Federation) and one in southern Europe (Slovenia) also exhibited increasing average annual rates, of 2.7%, 1.9%, and 2.6%, respectively. In northern Europe, rising rates were also found in Norway (AAPC: 1.4%) and in the Baltic countries of Latvia and Lithuania, with AAPC of 4.0% and 1.7%, respectively. In Asia, the rates increased in Singapore and more rapidly in Thailand and over the last decade (AAPC: 1.4% and 4.4%, respectively).
Among women, trends over time were similar to those in men. The greatest increases were seen in Thailand with an AAPC of 5.0% annually over the last 10 years, respectively. 
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In Europe, the Baltic countries including Latvia (5.7%) and Lithuania (2.5%) had large increases, followed by Slovenia (1.8%). Similar to men, increasing incidence rates in women were observed in Norway with an AAPC of 0.8%. In South America, rates in Brazil, Colombia and Ecuador increased annually by 3.3%, 1.5% and 1.1% respectively ( Table 2 . As with men, significantly decreasing trends in women were only seen in Japan (AAPC: -1.4%).
Discussion
This study describes the most recent patterns and trends in the incidence of brain and nervous system cancers in adults worldwide. Globally, a large variability in the magnitude of the diagnosis of new cases of brain and CNS cancer was found, with a 5-fold difference between the 
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highest and lowest rates in the populations represented in this study. By regions, the highest rates were found mainly in European countries, while the lowest rates were seen predominantly in Asian countries. Such differences may be partially related to the different genetic background of these populations. Common gene variants have recently been suggested 24 as influencing the risk of glioma, but this needs to be confirmed, while the prevalence of these variants in different world populations is not known. 25 Varying trends were observed globally but are sufficiently diffuse in different countries across continents to warrant a cautious approach to interpretation.
Trends in brain cancer incidence are complex to interpret given the vast array of different histological subtypes and potential artefacts linked to changing diagnostic approaches and registry practices. 26 The factors driving most of the temporal changes therefore appear to be common and have been likely driven by differences in reporting and completeness of registries in different countries. In addition, the limited number of known causative risk factors and the scarce related information on them at a country level makes interpretation of trends problematic. 27 In contrast to the marked geographical differences, temporal changes tended to be similar in both sexes, a gender pattern confirmed in previous studies. 17, [28] [29] [30] Decreasing incidence rates were observed only in Japan.
We observed increasing brain and CNS incidence in most South American countries. In Colombia, one of the countries where the largest increase was observed, a parallel increase in mortality has been reported. 31, 32 Though no data are available on the introduction and access to diagnostic technology for Colombia and other South American countries, the increasing patterns could be partially related to the improvement in access to diagnostic technology. 6 While the radiological accident with caesium-137 in Goiania (Brazil) in 1987 may have impacted on the rate of diagnosis in this region, 33, 34 it is noteworthy that compared with other world regions, testing of diagnostic radiological equipment prior to clinical use has been shown to be lower in Latin America. 35 Given the reported higher risk of death from CNS cancers in Brazil, a Brazilian study has assessed the role of occupational exposures, particularly to pesticides. 36 Colombia, Bolivia, and Ecuador have also been reported as being the highest users of pesticides relative to other Latin American countries, 37 although their role remains inconclusive. 11 We also found increasing incidence rates in most of the former Soviet Union countries. Radiofrequency emissions have been investigated as a risk factor for brain tumors. Although some studies have reported positive associations, [38] [39] [40] others have not. [41] [42] [43] [44] A recent study conducted in the Nordic countries (Denmark, Finland, Norway, and Sweden) revealed that although mobile phone use increased dramatically, the incidence of glioma remained almost constant between 1979 and 2008 in all 4 countries. 45 Due to the emerging findings on radiofrequency emission, it has been recently classified as a possible carcinogen in humans by the International Agency for Research on Cancer. Yet, the carcinogenic effect of non-ionizing radiofrequency remains unclear. 46 Incidence rates decreased significantly over the last decade in both sexes in Japan. A previous study by Kim et al 28 suggested that classification issues and exclusion of nonmalignant tumors from registry reporting may have been major contributors to this change over time. In Japan, a decreasing incidence has been reported over the period 1995-2004 in the Osaka Cancer Registry, and for the whole country, a decreasing trend has been observed since 1987. 47 Both these studies highlight the importance of comparable inclusion criteria to enable valid comparison between registration systems. CT scan examinations have significantly higher radiation than normal X-rays 48 and have been associated with brain cancer. 49 The decreasing trends observed in Japan contrast strongly with the available information on the use of CT scan; Japan is one of the major users of CT scans worldwide, and their number has increased significantly over the last years. 48 This supports the prospects of possible underlying reporting and classification issues for the explanation of the observed decreasing trends.
Asides from the possibility of genuine differences in risk among different ethnic groups, reported difference in incidence rates by race/ethnicity in the US might be explained in part by access to health care, reflecting social inequalities. 50 Wrensch and colleagues (2002) 51 suggested that variations in socioeconomic status may in part explain the higher rates among US whites relative to US blacks. Other studies have observed an elevated rate of brain and nervous system cancers among individuals with higher education levels. 52 From a global perspective, the recent increase in incidence rates in countries in transition (eg, Brazil, Colombia, Costa Rica, Thailand, Ecuador, the former Eastern bloc countries) may be partly due to economic growth and consequently increased access to health care and improved diagnosis of this cancer. 17 We observed that men had on average a 40% higher incidence of brain and CNS cancer than women, which was consistent with data published from Japan 47 and the United States. 8 It has been suggested that gender differences related to sex hormones and genetic features 53 may be causative factors. In addition, adverse working conditions, including a higher exposure to pesticides, chemicals, and biological agents, among men may contribute. 54 This is the first contemporary report providing a global analysis examining the geographic and temporal variations in brain and CNS cancer. Although great care has been taken to include only high (CI5) quality registration data, variations in the practices with regard to the reporting of these cancers persist. This renders comparison of temporal trends of brain and CNS cancers between population-based cancer registries particularly challenging. We noted different incidence trends (Supplementary Figure 1) in Sweden, Denmark, and Norway on comparing CI5 18 with other datasets obtained from the European Cancer Observatory (EUREG 19 data that includes only malignant brain and CNS tumors), and NORDCAN, 55 includes both malignant and nonmalignant tumors). Nonmalignant tumors were possibly included in Sweden in the CI5 data from 2001, while in Denmark nonmalignant tumors may have been included until 1998; this calls for a careful assessment of international comparisons of secular trends in incidence of brain tumors.
The results presented in this study indicate important regional and country variations in brain and CNS cancers worldwide. They provide important insights into further etiological research and put a focus on the role of environmental risk factors, including radiofrequency fields and occupational exposures, particularly pesticides and chemicals. The observed variations in countries with differing levels of resources could partly be explained by contrasts in health systems infrastructure, access to care, and the availability of diagnostic services. Special attention should be given to addressing quality and availability of incidence data in low and medium income countries. Better documentation of the recording process and the specific inclusion or exclusion criteria of nonmalignant neoplasms is also called for. Finally, comparative studies by histological type and birth cohort analyses could provide further insight into the epidemiology of these complex and lifethreatening groups of cancers.
Supplementary Material
Supplementary material is available at Neuro-Oncology online.
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